Auron Presents Preclinical Data on AUTX-703 at 2025 AACR Meeting
28 Apr 2025 //
GLOBENEWSWIRE
Auron presents preclinical data for AUTX-703 in Lung Cancer
03 Apr 2025 //
GLOBENEWSWIRE
Auron Therapeutics to Present Poster at 2025 AACR Meeting
26 Mar 2025 //
GLOBENEWSWIRE
Auron Therapeutics Appoints Glenn Goddard As CFO
19 Mar 2025 //
GLOBENEWSWIRE
Auron’s AUTX-703 Gets FDA Fast Track For Acute Myelogenous Leukemia
24 Feb 2025 //
GLOBENEWSWIRE
Auron Receives FDA Clearance for AUTX-703 & Series B Financing
04 Feb 2025 //
GLOBENEWSWIRE
Auron Presents Preclinical Data for AUTX-703 in AML at ASH 2024
09 Dec 2024 //
GLOBENEWSWIRE
Auron Presents Preclinical Data on AUTX-703 at ASH 2024 Meeting
05 Nov 2024 //
GLOBENEWSWIRE
Auron Presents New Data For AUTX-703 Across Cancer Types
24 Oct 2024 //
GLOBENEWSWIRE
Auron Announces Presentation at 2024 PCF Annual Scientific Retreat
11 Oct 2024 //
GLOBENEWSWIRE
Auron to Present AUTX-703 Preclinical Data 2024 ENA Symposium
09 Oct 2024 //
GLOBENEWSWIRE
Auron Presents Preclinical Data at American Chemical Society Annual Meeting
19 Aug 2024 //
GLOBENEWSWIRE
Auron: AURIGIN„ Platform Preclinical Data At AI Symposia
01 May 2024 //
GLOBENEWSWIRE
Auron Reveals Preclinical Data on AURIGIN Platform at AACR
10 Apr 2024 //
GLOBENEWSWIRE
Auron Reveals AURIGIN Platform Data at AACR Meeting
09 Apr 2024 //
GLOBENEWSWIRE
Auron Announces Poster Presentations at 2024 AACR Annual Meeting
06 Mar 2024 //
GLOBENEWSWIRE
Auron Selects First Development Candidate for Targeted Cancer Treatments
08 Feb 2024 //
GLOBENEWSWIRE
Auron Strengthens Board of Directors with Victoria Richon & Christopher Guiffre
10 Aug 2023 //
GLOBENEWSWIRE
Auron Establishes Scientific Advisory Board to Support AI-Powered Platform
01 Aug 2023 //
GLOBENEWSWIRE